Unlike cytotoxic agents that indiscriminately affect rapidly dividing cells, newer
antineoplastic agents such as targeted therapies and immunotherapies are associated with …

Tyrosine kinase inhibitors (TKIs) are currently used by most oncologists. Among their side
effects, thyroid dysfunctions are nowadays clearly observed. Whereas changes in thyroid …

Patients diagnosed with advanced gastrointestinal stromal tumor (GIST) are currently treated
with oral tyrosine kinase inhibitors (TKIs). Imatinib mesylate is the standard first-line …

Tyrosine kinase inhibitors (TKIs) have improved outcome for many tumors. Although better
tolerated than cytotoxic chemotherapy, they may cause several adverse events (AEs) and …

Background: Several of the currently used anticancer drugs may variably affect thyroid
function, with impairment ranging from modified total but not free concentration of thyroid …

Context: The use of kinase inhibitors (KIs) in the treatment of cancer has become
increasingly common, and practitioners must be familiar with endocrine-related side effects …

Context: Tyrosine kinase inhibitors (TKI) are used for the treatment of various cancers. Case
reports and clinical trials have reported abnormal thyroid function tests (TFT) after treatment …

The most recent World Health Organization classification of renal neoplasms encompassed
nearly 50 distinctive renal neoplasms. Different histological subtypes have different clinical …

Background: Thyroid dysfunction is a well-known adverse effect of first-generation tyrosine
kinase inhibitors (TKIs), like sunitinib. The aim of this study was to investigate the effect of …

Introduction: Recently, tyrosine kinase inhibitors (TKIs) have emerged as a new class of
anticancer therapy. Although generally considered less toxic than cytotoxic chemotherapy …